Manas AI key facts
- Developer of a full-stack, artificial intelligence-driven drug discovery platform designed to reduce drug development timelines.
- It has raised $50.6M; the latest was Seed Round ($50.6M) in Apr 2025.
- Notable investors include General Catalyst, Endeavor Catalyst, Greylock, The General Partnership, Next Play Ventures — 11 tracked in total.
- Status: Privately Held (backing).
Manas AI leadership
- Jonathan BaellChief Scientific Officer
- Ujjwal SinghChief Technology Officer & Founder
Who backs Manas AI
11+- ·The complete investor list: 11 names
- ·Watch Manas AI: the Monday email on marks, rounds and moves
Manas AI funding rounds
No funding rounds for Manas AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Manas AI investors
11 investors are on record for Manas AI, including General Catalyst, Endeavor Catalyst, Greylock and The General Partnership. By type, the record holds 7 venture capital firms.
Who runs Manas AI
8 people are listed on the Manas AI team: 2 executives and 6 board members, including Ujjwal Singh (Chief Technology Officer) and Jonathan Baell (Chief Scientific Officer). 7 of them have a verified direct contact on file.
About Manas AI
Developer of a full-stack, artificial intelligence-driven drug discovery platform designed to reduce drug development timelines. The company offers proprietary AI models, generative computational chemistry, and biology, enabling clients to streamline development and improve efficiency.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 8
- Website
- manasai.co/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Manas AI doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.